This study is comparing two anti-clotting medications, ticagrelor (60mg twice daily) and clopidogrel (75mg daily), in patients with stable coronary artery disease (CAD) who are having an elective procedure to open blocked heart arteries (percutaneous coronary intervention or PCI). All participants will also take aspirin (81mg daily). We want to see if ticagrelor works better than clopidogrel at preventing blood clots, which is measured by a test called P2Y12 reaction units (PRU) after about 30 days. You might be able to join if you are 18 or older, have stable CAD, and have a specific score (ABCD-GENE score of 10 or higher) that indicates a higher risk for clotting problems. The study is currently recruiting about 50 participants, but its overall status is unclear.

Study design

This is an interventional study comparing two different drug treatments. It plans to enroll about 50 participants.

What's involved

Participants will receive either ticagrelor or clopidogrel for about 30 days, along with aspirin. The primary measurement is taken at 30 days.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at 30 days after starting the study medication.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.